Sector: MedicalOXiGENE, Inc. (NASDAQ: OXGN)
Headlines
- OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference
Nov 17, 2009 12:31 PM | OXGN
- OXiGENE to Present at American Society of Hematology and AACR/NCI/EORTC Meetings
Nov 12, 2009 04:01 PM | OXGN
- OXiGENE to Present at Merriman Curhan Ford and Lazard Healthcare Conferences
Nov 10, 2009 02:01 AM | OXGN
- OXiGENE Reports Third Quarter 2009 Financial Results
Nov 09, 2009 02:01 AM | OXGN
- OXiGENE Announces Third Quarter 2009 Earnings Conference Call and Webcast
Nov 03, 2009 02:00 AM | OXGN
- Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of VaxGen, Inc.
Oct 22, 2009 06:00 PM | OXGN, VXGN
- Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of VaxGen, Inc. - VXGN.OB
Oct 21, 2009 01:14 PM | OXGN, VXGN
- OXiGENE Announces Data Presentation At 2009 AACR-EORTC-NCI Conference
Oct 12, 2009 08:04 AM | OXGN
- Oxigene Announces Management Changes
Oct 08, 2009 08:01 AM | OXGN
- Summary Of Company Studies From ASCO Conference
Jun 05, 2006 04:05 PM | AEZS, ALTH, BIVN, KERX, MEDX, MRK
- OXiGENE to Acquire VaxGen in a Stock-for-Stock Merger
Oct 15, 2009 06:53 AM | OXGN, VXGN
- OXiGENE Reports Second Quarter 2009 Financial Results; Company Continues to Achieve Pipeline Progress With Strengthened Cash Position
Jul 30, 2009 02:00 AM | OXGN
- OXiGENE Announces Second Quarter 2009 Earnings Conference Call and Webcast
Jul 24, 2009 02:00 AM | OXGN
- OXiGENE Announces Closing of Registered Direct Offering
Jul 21, 2009 02:00 AM | OXGN
- OXiGENE to Raise $10 Million in Registered Direct Offering
Jul 15, 2009 09:54 AM | OXGN
- Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
Jul 13, 2009 08:31 AM | ACCP, CYTX, ECTE, JLI, NABI
- OXiGENE Announces Agreement to Acquire Symphony ViDA, Including More Than $12 Million in Unrestricted Cash and All Rights to OXi4503 and ZYBRESTAT for Ophthalmology
Jul 06, 2009 02:00 AM | OXGN
- OXiGENE Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology
Jun 25, 2009 02:00 AM | OXGN
- OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer
Jun 17, 2009 02:01 AM | OXGN
- OXiGENE Reports Positive Data From Phase 2 Trial of ZYBRESTAT in Platinum Resistant Ovarian Cancer At the 2009 ASCO Annual Meeting
Jun 01, 2009 10:45 AM | OXGN
- Form 4 FICKLING ROY H For: Sep 30 (10K)
Oct 05, 2009 12:21 PM
- Form 4 LAFFER ARTHUR B For: Sep 30 (10K)
Oct 05, 2009 12:21 PM
- Form 4 Schwieterman William D For: Sep 30 (10K)
Oct 05, 2009 12:20 PM
- Form 4 SHIEBLER WILLIAM N For: Jan 20 (10K)
Sep 18, 2009 04:29 PM
- Form 4 Schwieterman William D For: Jan 20 (10K)
Sep 18, 2009 04:28 PM
- Form 4 LAFFER ARTHUR B For: Jan 20 (10K)
Sep 18, 2009 04:27 PM
- Form 4 FICKLING ROY H For: Jan 20 (10K)
Sep 18, 2009 04:25 PM
- Form 4 TARANTO HARRI V For: Jul 20 (10K)
Aug 12, 2009 06:55 PM
- Form 3 TARANTO HARRI V For: Oct 01 (10K)
Aug 12, 2009 06:48 PM
- Form 4 KESSEL MARK For: Jul 20 (10K)
Jul 22, 2009 05:31 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
OXGN
|
Compare to S&P
|
| YTD |
89.39 %
|
56.75 %
|
| 4 Weeks |
1.63 %
|
0.53 %
|
| 12 Weeks |
-13.19 %
|
-18.16 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -154.55 %
|
|
EPS Growth in Last Year: -12.00 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
